VYGR

Voyager Therapeutics Inc

VYGR, USA

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

https://www.voyagertherapeutics.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VYGR
stock
VYGR

Is VYGR stock trading at a premium valuation - Weekly Trade Summary & Stock Timing and Entry Methods Улправда

Read more →
VYGR
stock
VYGR

Is VYGR stock trading at a premium valuation - July 2025 Review & Precise Swing Trade Entry Alerts Улправда

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$15

Analyst Picks

Strong Buy

11

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.18

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.69 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.67 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-233.86 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.31

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 66.85% of the total shares of Voyager Therapeutics Inc

1.

BlackRock Inc

(10.3334%)

since

2025/06/30

2.

Armistice Capital, LLC

(8.6535%)

since

2025/06/30

3.

EcoR1 Capital, LLC

(7.0626%)

since

2025/06/30

4.

Vanguard Group Inc

(5.7869%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(3.0232%)

since

2025/07/31

6.

Vestal Point Capital LP

(2.6592%)

since

2025/06/30

7.

Dimensional Fund Advisors, Inc.

(2.5621%)

since

2025/06/30

8.

iShares Russell 2000 ETF

(2.0572%)

since

2025/08/31

9.

Geode Capital Management, LLC

(2.0135%)

since

2025/06/30

10.

Erste Asset Management GmbH

(2.0134%)

since

2025/06/30

11.

Millennium Management LLC

(1.6282%)

since

2025/06/30

12.

State Street Corp

(1.6116%)

since

2025/06/30

13.

Farallon Capital Management, L.L.C.

(1.289%)

since

2025/06/30

14.

T. Rowe Price Associates, Inc.

(1.1013%)

since

2025/06/30

15.

Bank of America Corp

(1.0393%)

since

2025/06/30

16.

Morgan Stanley - Brokerage Accounts

(1.0158%)

since

2025/06/30

17.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8551%)

since

2025/07/31

18.

Fidelity Small Cap Index

(0.8324%)

since

2025/06/30

19.

Vanguard Explorer Inv

(0.824%)

since

2025/06/30

20.

UBS Group AG

(0.8213%)

since

2025/06/30

21.

BlackRock Health Sciences Opps Inv A

(0.7679%)

since

2025/07/31

22.

iShares Russell 2000 Value ETF

(0.7339%)

since

2025/08/31

23.

Northern Trust Corp

(0.7292%)

since

2025/06/30

24.

Renaissance Technologies Corp

(0.7069%)

since

2025/06/30

25.

T. Rowe Price Health Sciences

(0.6248%)

since

2025/07/31

26.

Royal Bank of Canada

(0.523%)

since

2025/06/30

27.

AQR Capital Management LLC

(0.5106%)

since

2025/06/30

28.

Goldman Sachs Group Inc

(0.5064%)

since

2025/06/30

29.

DFA US Targeted Value I

(0.4922%)

since

2025/07/31

30.

iShares Biotechnology ETF

(0.4836%)

since

2025/08/31

31.

Fidelity Extended Market Index

(0.4424%)

since

2025/07/31

32.

BlackRock Advantage Small Cap Core Instl

(0.4408%)

since

2025/07/31

33.

Dimensional US Targeted Value ETF

(0.4061%)

since

2025/08/29

34.

Vanguard Russell 2000 ETF

(0.4039%)

since

2025/07/31

35.

BlackRock Health Sciences Term Trust

(0.3819%)

since

2025/06/30

36.

JPM Thematics Genetic Thrps C2 dist USD

(0.351%)

since

2025/07/31

37.

ERSTE STOCK BIOTEC EUR R01 A

(0.3406%)

since

2025/07/31

38.

State St Russell Sm Cap® Indx SL Cl I

(0.2912%)

since

2025/08/31

39.

Bridge Builder Tax Managed Sm/Md Cp

(0.2832%)

since

2025/08/31

40.

DFA US Small Cap Value I

(0.2508%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.47

EPS Estimate

-0.521

EPS Difference

0.051

Surprise Percent

9.7889%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.